Status:
COMPLETED
Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial
Lead Sponsor:
Australian and New Zealand Intensive Care Research Centre
Conditions:
Cardiac Failure
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine in patients requiring venoarterial (V-A) ECMO, whether the use of a conservative as compared with liberal oxygen strategy, results in a greater number of ICU-free days at day 28.
Detailed Description
Extracorporeal membrane oxygenation (ECMO) can be a lifesaving procedure for the sickest patients in the Intensive Care Unit (ICU) who are at risk of death from severe cardiac and respiratory failure....
Eligibility Criteria
Inclusion
- • Patients ≥18 years who are commenced on V-A ECMO for severe cardiac, or following refractory cardiac arrest.
Exclusion
- Greater than 6 hours have elapsed from the time of initiation of ECMO to randomisation
- Patients who are suspected or confirmed to be pregnant
- Where an indication exists for a specific oxygen target as part of clinical care (e.g. carbon monoxide poisoning)
- Patients who are already enrolled in another oxygen titration study (unless agreed by study committees)
- Patients not willing to receive blood products (e.g. Jehovah's Witness)
- Where the treating physician deems the study is not in the patient's best interest
Key Trial Info
Start Date :
September 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03841084
Start Date
September 18 2019
End Date
July 1 2023
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Health
Melbourne, Victoria, Australia, 3004